AU2012242684B2 - Diagnostic markers and therapeutic targets of Kawasaki disease - Google Patents

Diagnostic markers and therapeutic targets of Kawasaki disease Download PDF

Info

Publication number
AU2012242684B2
AU2012242684B2 AU2012242684A AU2012242684A AU2012242684B2 AU 2012242684 B2 AU2012242684 B2 AU 2012242684B2 AU 2012242684 A AU2012242684 A AU 2012242684A AU 2012242684 A AU2012242684 A AU 2012242684A AU 2012242684 B2 AU2012242684 B2 AU 2012242684B2
Authority
AU
Australia
Prior art keywords
biomarker
level
acc
meprin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2012242684A
Other languages
English (en)
Other versions
AU2012242684A1 (en
Inventor
Alex Kentsis
Susan Kim
Hanno Steen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2012242684A1 publication Critical patent/AU2012242684A1/en
Application granted granted Critical
Publication of AU2012242684B2 publication Critical patent/AU2012242684B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012242684A 2011-04-15 2012-04-13 Diagnostic markers and therapeutic targets of Kawasaki disease Expired - Fee Related AU2012242684B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161475936P 2011-04-15 2011-04-15
US61/475,936 2011-04-15
US201161579007P 2011-12-22 2011-12-22
US61/579,007 2011-12-22
PCT/US2012/033514 WO2012142409A2 (en) 2011-04-15 2012-04-13 Diagnostic markers and therapeutic targets of kawasaki disease

Publications (2)

Publication Number Publication Date
AU2012242684A1 AU2012242684A1 (en) 2013-10-31
AU2012242684B2 true AU2012242684B2 (en) 2017-04-20

Family

ID=46208753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012242684A Expired - Fee Related AU2012242684B2 (en) 2011-04-15 2012-04-13 Diagnostic markers and therapeutic targets of Kawasaki disease

Country Status (8)

Country Link
US (1) US9869673B2 (enExample)
EP (2) EP3086121A1 (enExample)
JP (1) JP6072768B2 (enExample)
KR (1) KR20140034193A (enExample)
CN (2) CN103562725B (enExample)
AU (1) AU2012242684B2 (enExample)
CA (1) CA2833257A1 (enExample)
WO (1) WO2012142409A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137907A4 (en) * 2014-05-02 2018-02-28 Momenta Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of kawasaki disease
JP6779200B2 (ja) * 2014-07-24 2020-11-04 アカデミア シニカ 川崎病の診断及び治療
KR102056405B1 (ko) * 2018-04-05 2019-12-16 (주)메디젠휴먼케어 Ebf2 유전자 다형성을 이용한 가와사키병 발병 예측 방법
CN110763845B (zh) * 2018-07-27 2022-10-28 成都市第三人民医院 一种检测蛋白标志物的配体在制备用于诊断结肠癌的产品中的用途和试剂盒
TWI704349B (zh) * 2019-06-17 2020-09-11 高雄榮民總醫院 蛋白質生物標記用以診斷川崎症的用途
US20240263234A1 (en) * 2020-10-02 2024-08-08 Mitsuru MIYATO Method for predicting development of severe symptom of covid-19 using exosomal protein marker in blood
CN116087519B (zh) * 2021-05-17 2025-03-14 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
KR102705469B1 (ko) * 2022-05-30 2024-09-11 충남대학교산학협력단 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
WO2007003594A1 (en) 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
JP4795037B2 (ja) 2006-02-01 2011-10-19 財団法人 神戸市地域医療振興財団 川崎病の判定方法及びそのためのキット
WO2007142347A1 (ja) 2006-06-05 2007-12-13 Shimadzu Corporation 腫瘍マーカー及び癌疾病の罹患の識別方法
WO2009046267A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US20110311443A1 (en) * 2009-03-06 2011-12-22 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EBATA, R. et al., "Increased production of vascular endothelial growth factor-D and lymphangiogenesis in acute Kawasaki Disease", Circulation Journal, 2011, vol. 75, pages 1455 - 1462 (Available online 12 April 2011) *
HUANG, M.Y. et al., "Acute-phase reactants and a supplemental diagnostic aid for Kawasaki Disease", Pediatric Cardiology, 2011, Vol. 31, pages 1209 - 1213 *
KANEKO, K. et al, "Prediction of the risk of coronary arterial lesions in Kawasaki Disease by brain natriuretic peptide", Pediatric Cardiology, 2011, vol. 32, pages 1106 - 1109 (Available online 13 April 2011) *

Also Published As

Publication number Publication date
US20140161791A1 (en) 2014-06-12
WO2012142409A2 (en) 2012-10-18
AU2012242684A1 (en) 2013-10-31
JP2014512014A (ja) 2014-05-19
EP2697653B1 (en) 2016-03-30
US9869673B2 (en) 2018-01-16
JP6072768B2 (ja) 2017-02-01
KR20140034193A (ko) 2014-03-19
WO2012142409A3 (en) 2013-02-28
CA2833257A1 (en) 2012-10-18
CN103562725B (zh) 2016-08-17
EP3086121A1 (en) 2016-10-26
CN106053835A (zh) 2016-10-26
EP2697653A2 (en) 2014-02-19
CN103562725A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
US9869673B2 (en) Diagnostic markers and therapeutic targets of kawasaki disease
Nagalla et al. Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers
CA3052349C (en) Proadm as marker indicating an adverse event
EP4045912A1 (en) Apparatuses and methods for detection of pancreatic cancer
CN109564225B (zh) 作为指示不良事件的标志物的组蛋白和/或proADM
EP3149192B1 (en) Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
US20130116343A1 (en) Salivary Protein Markers for Detection of Breast Cancer
US20140329251A1 (en) Ltbp2 as a biomarker for lung injury
US20110269162A1 (en) Ubiquitin proteasome system profiling for diagnosis of chronic liver disease
WO2008145701A1 (en) Method for predicting the outcome of a critically ill patient
CN117242350A (zh) 用于脓毒症的早期检测的il6标志物组
US7871787B2 (en) Methods for diagnosing endometriosis
KR20200080183A (ko) 치주질환 진단 방법, 이를 위한 조성물 및 키트
HK1193650A (en) Diagnostic markers and therapeutic targets of kawasaki disease
정영화 Proteomic identification of early urinary-biomarkers of acute kidney injury in preterm infants
Krishna Sumanth et al. Evolution of proteomic biomarker for chronic liver disease Promise into reality
Raziq et al. Correlating Serum Biomarkers with Clinical Outcomes in Pediatric Sepsis; A Retrospective Observational Study
HK40017069A (en) Proadm as marker indicating an adverse event

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee